Drug development is often considered a 'failure-prone industry.' However, by implementing risk management strategies based on scientific evidence, we aim to minimize failure rates due to toxicity.

• Make informed Go/No-Go decisions in drug development by analyzing the risk-benefit profile at the non-clinical stage.
• Address toxicity challenges in new drug candidates during the early stages of development.
• Enhance non-clinical testing techniques through the development and dissemination of advanced toxicity assessment methods.
• Develop an autonomous failure management system for the pharmaceutical industry and facilitate its practical application through analytical algorithm development and dissemination.
• Foster skilled professionals through continuous education and training.